Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ondine Biomedical Inc. | OBI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.25 | 2.50% | 10.25 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.25 | 10.25 | 10.25 | 10.25 | 10.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 19/3/2025 07:15 by bamboo2 Third trial underway.This is a pilot study in a new area of the hospital [ICU] for Ondine. ==================== 19 March 2025 ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or the "Company") First patients recruited into Steriwave ICU pilot study and related Issue of Shares Ondine Biomedical Inc. (LON: OBI), a global leader in light-activated antimicrobial technologies, is pleased to announce that patient recruitment has commenced in an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. Treating patients in intensive care units (ICUs) with Ondine's Steriwave® nasal photodisinfection technology would significantly expand the market opportunity for Steriwave. Infection prevention is a top priority in ICUs, where higher infection rates, critically ill patients, and bed capacity shortages create significant challenges. Unlike traditional antibiotics, Steriwave does not generate antimicrobial resistance. Already in use across Canada and in several UK NHS trusts before major surgery, this technology helps reduce the incidence of surgical site infections (SSIs) by decolonizing the nose-a major reservoir of infection-causing pathogens. The first patients were enrolled at RCH on 18 March 2025 for the four-month pilot involving approximately 400 ICU patients. This important study aims to evaluate the feasibility of conducting a larger safety and efficacy study of Steriwave in reducing hospital-acquired infections (HAIs) among critically ill patients in the ICU. HAIs, often caused by multidrug-resistant organisms, represent a growing challenge to healthcare systems worldwide. RCH, a level 1 trauma centre and one of the busiest in Canada, is the first to explore the use of Ondine's Steriwave nasal decolonization technology in ICUs. Conducted by ICU physician, Dr. Reynolds and his research team, this pilot study will evaluate how Steriwave can integrate into ICU infection control and workflow protocols and will make a preliminary assessment of its potential impact on infection rates, length of stay and patient mortality. This Investigator-Initiat Carolyn Cross, CEO of Ondine Biomedical, commented: "This trial represents a significant step forward in our mission to bring innovative infection prevention technologies to the most vulnerable patients. Partnering with Royal Columbian Hospital allows us to advance Steriwave's potential as a game-changing technology in ICU infection prevention practices." ICUs are often a hotbed for HAIs, with critically ill patients at heightened risk due to their compromised conditions and invasive procedures. In Canada alone, hundreds of thousands of ICU patients each year face a 12-13% risk of developing infections unrelated to their primary condition.[1] Antimicrobial resistance (AMR) has further complicated treatment, with resistance rates climbing to concerning levels. A landmark 2012 HCA Healthcare study involving nearly 75,000 ICU patients found that universal nasal decolonization using the antibiotic mupirocin reduced all-cause bloodstream infections by 44%.[2] However, reliance on mupirocin is increasingly risky-not only due to resistance rates as high as 80%[3] but also because its limited spectrum leaves patients vulnerable to pathogens it cannot address, underscoring the urgent need for innovative alternatives. Ondine's Steriwave is a non-invasive and painless treatment that uses a proprietary light-activated antimicrobial agent to destroy harmful pathogens, including bacteria, viruses, and fungi, in the nasal passages. The treatment is effective immediately, takes less than five minutes, and allows the normal nasal microbiome to recover swiftly. This groundbreaking approach offers a potentially life-saving solution for ICU patients, addressing a critical gap in infection prevention. Share Issuance Linked to Milestone Achievement As part of the clinical trial agreement, milestone payments to the trial site are payable in equity. Ondine Biomedical will issue shares equivalent to 25% of the agreed C$855,000 study cost for the second milestone of enrolling the first patient in the trial. The Company will issue 1,178,365 new ordinary shares of no par value in the capital of the Company ("Common Shares") at an issue price of 9.75 pence, reflecting the closing price of the Company's shares two business days preceding the first-patient-enrolm Admission, Settlement and Dealings Admission of the 1,178,365 new Common Shares will take place on or around 8.00 a.m. on 25 March 2025. The new Common Shares when issued, will be fully paid and will rank pari passu in all respects with the existing Common Shares in the Company, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Total Voting Rights Following Admission, the Company's issued and fully paid share capital will consist of 443,233,174 Common Shares, each carrying one voting right per Common Share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company following Admission will be 443,233,174. This figure may be used from the date of Admission until further notice by existing shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. All references to C$ in this announcement are to Canadian Dollars. This Announcement uses a C$:£ exchange rate of 1 : 0.5375 as at 16:30 (GMT) on 12 March 2025. |
Posted at 26/2/2025 08:10 by bamboo2 26 February 2025 ONDINE BIOMEDICAL INC.Ondine Biomedical Strengthens Leadership Team with the Appointment of Michael Behlke as non-Board CFO & COO Ondine Biomedical Inc. (LON: OBI), a global leader in light-activated antimicrobial treatments, is pleased to announce the appointment of Michael S. Behlke as Chief Financial Officer (CFO) and Chief Operating Officer (COO), effective immediately. Recognized in the US MedTech community for his career achievements, Mr. Behlke brings over 30 years of financial and operational leadership experience, positioning Ondine for accelerated growth and commercialization success. Mr. Behlke's distinguished career includes securing over $250 million in funding, supporting acquisitions exceeding $700 million, and driving commercialization strategies for emerging and mid-stage medical companies. Prior to joining Ondine, he served as CFO and Acting COO at Ventec Life Systems with full P&L responsibility, where he played a critical role in scaling the company's revenue from $13 million to $500 million annually and in its landmark partnership with General Motors to rapidly scale up and manufacture ventilators for the US Strategic National Stockpile during the COVID-19 pandemic. Carolyn Cross, Ondine's Chief Executive Officer: "We are thrilled to welcome Michael to our leadership team. Ondine is at a critical inflection point as we expand our hospital-based infection prevention solutions. Michael's extensive MedTech industry experience, operational leadership, and business transformation successes will be key to accelerating our worldwide commercialization efforts, initially within Canada and the UK/EU, and then rapidly expanding into the U.S. post-FDA approval." In his new role, Mr. Behlke will oversee Ondine's capital markets strategies, operational efficiency, and international expansion, ensuring the company's is well-positioned for sustained growth and market leadership. His deep expertise in P&L management, business transformation, and supply chain execution will be key to advancing Ondine's mission of revolutionizing infection prevention through its photodisinfection-ba Michael Behlke, CFO & COO of Ondine Biomedical: "I am honored to join Ondine at this pivotal moment. The company's groundbreaking photodisinfection technology represents a paradigm shift in infection control. I look forward to working with this talented team to drive operational excellence, financial growth, and global adoption of this life-saving technology." This appointment strengthens Ondine's leadership team and underscores the Company's commitment to expanding its footprint in key global markets and addressing the urgent need for innovative antimicrobial solutions in healthcare settings. |
Posted at 06/2/2025 11:04 by someuwin RNS Number : 2072WOndine Biomedical Inc. 06 February 2025 ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or the "Company") Ondine President increases shareholding Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Nicolas Loebel, President and CTO, has purchased 25,000 shares ("Common Shares") in the Company at a price of 12.6 pence per Common Share on 05 February 2025. Following this transaction, Nicolas Loebel holds 3,538,991 Common Shares representing 0.8006% of the issued share capital of the Company. |
Posted at 04/2/2025 09:47 by someuwin RNS Number : 7578VOndine Biomedical Inc. 04 February 2025 ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or the "Company") Ondine CEO increases shareholding in Company as Phase 3 clinical trial progresses Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that The Pennycook Family Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband of Carolyn Cross, has purchased 149,225 shares ("Common Shares") in the Company at a price of 12.5 pence per Common Share on 03 February 2025. Following this transaction, Carolyn Cross and Robert Cross, directly and indirectly, hold 156,314,029 Common Shares representing 35.3621% of the issued share capital of the Company. |
Posted at 03/2/2025 08:34 by bamboo2 jb, Interesting that CC keeps adding. I must admit at first I thought your post was a reminder of the prior buy earlier last week.==================== 03/02/2025 Ondine CEO adds to stake in Company as Phase 3 clinical trial progresses Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that The Pennycook Family Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband of Carolyn Cross, has purchased 100,000 shares ("Common Shares") in the Company at a price of 12.5 pence per Common Share on 31 January 2025. Following this transaction, Carolyn Cross and Robert Cross, directly and indirectly, hold 156,164,804 Common Shares representing 35.3284%% of the issued share capital of the Company. |
Posted at 27/1/2025 07:49 by bamboo2 HCA to invest US$4 million in OndineThis Announcement uses a US$:£ exchange rate of 1 : 0.808210 as at 16:30 (GMT) on 2 January 2025. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company developing light-activated antimicrobial treatments, is pleased to announce that hInsight-NX, LLC, a subsidiary of HCA Healthcare, Inc., a leading healthcare provider in the United States, has committed to a US$4 million equity investment in the Company. The Company has agreed to issue 38,033,412 new common shares of no par value in the capital of the Company ("New Common Shares"), raising US$4 million (circa £3,232,840) at an issue price of approximately US$0.10517 per New Common Share (the "Private Placement"). The price of the subscription was determined by reference to the price the Company raised C$19.2 million in November 2024. The New Common Shares to be issued pursuant to the Private Placement will represent approximately 8.6041 per cent of the share capital of the Company as enlarged by the Private Placement. The shares will be issued non pre-emptively under the Company's existing authorities and are expected to be admitted to trading on AIM on 29 January 2025. The New Common Shares, when issued, will be fully paid and will rank pari passu in all respects with the existing common shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Use of Proceeds The proceeds from this investment will be used to support the Company's strategic objectives, including advancing key initiatives, to deliver long-term value. With the addition of this new investment, the Company expects its cash runway to extend into early Q4 2025. Total Voting Rights Following admission of the New Common Shares on 24 January 2025, the Company's issued and fully paid share capital will consist of 442,038,143 Common Shares, all of which carry one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company at this date will be 442,038,143 Common Shares. This figure may be used from the date of Admission until further notice by Existing Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. Other Update As previously announced, Ondine entered into a private placement agreement with a Canadian private investor in September 2024. Due to the investor's unavoidable personal circumstances, settlement of the private placement continues to be delayed. The Company remains optimistic about the completion of this placement and will provide further updates as they become available. |
Posted at 30/12/2024 08:52 by bamboo2 4,999 to go!Good to see this get going before year end. ==================== Ondine recruits first patient for US Phase 3 trial Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, has enrolled and treated the first patient in the Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections ('LANTERN') Phase 3 clinical trial. The trial, involving approximately 5,000 patients in 14 hospitals, is evaluating Ondine's non-antibiotic nasal photodisinfection technology, branded as Steriwave® outside the US. The first patient was enrolled at Centennial Medical Center in Nashville, Tennessee, on Friday December 27th, 2024. The Phase 3 trial is being conducted in collaboration with HCA Healthcare, a leading healthcare provider in the United States. This group-randomized crossover study will enroll approximately 5,000 surgical patients undergoing cardiac, orthopaedic, vascular, neurosurgical or radical mastectomy procedures. The study will compare standard infection prevention practices with, and without, Ondine's nasal photodisinfection technology in order to reduce the incidence of surgical site infections. The final patient is expected to enroll in mid-2025, and preliminary trial results are projected for release in Autumn 2025. Ondine Biomedical's CEO Carolyn Cross said: "Our US Phase 3 trial initiation is an exciting milestone towards making photodisinfection technology available to healthcare professionals who want to rapidly eliminate a broad spectrum of infection-causing pathogens without fuelling drug resistance or relying on patient compliance as is the case with topical antibiotics." Ondine's nasal photodisinfection is a 5-minute, non-invasive procedure that rapidly decolonizes the nose of infection-causing pathogens without the use of antibiotics. This innovative approach avoids contributing to antimicrobial resistance (AMR). The process involves applying a proprietary photosensitive agent to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light. The light activates the agent, producing an oxidative burst that destroys bacteria, viruses and fungi in a single treatment. Nasal decolonization is recommended in the 2016 WHO Global guidelines for the prevention of surgical site infections,[1] and the Society for Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023, recommend nasal decolonization for major surgical procedures.[2] |
Posted at 17/12/2024 07:22 by bamboo2 Ondine commencing US Phase 3 clinical trialOndine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces the imminent start of the LANTERN Phase 3 clinical trial of its novel nasal photodisinfection technology, branded as Steriwave® outside the US. The U.S. Food and Drug Administration (FDA) has raised no objections to starting the study during its statutory 30-day review period of the Company's Investigational New Drug (IND) amendment, thereby allowing the trial to begin. Preparations for this pivotal trial are nearly complete, with all 14 hospital sites selected and two additional back-up sites identified. Ondine has already initiated four sites and has been conducting staff training to ensure readiness for patient enrolment. Patient recruitment activities are beginning and will continue through early 2025, with the final patient expected to enrol in mid-2025. Early trial results are projected for release in Autumn 2025. The Phase 3 trial is being conducted in collaboration with HCA Healthcare, a leading healthcare provider in the United States. This group-randomized crossover study will enroll approximately 5,000 surgical patients undergoing cardiac, orthopedic, vascular, neuro or radical mastectomy surgeries. The study will compare standard infection prevention practices with and without Ondine's nasal photodisinfection technology. CEO Carolyn Cross stated: "The significant recent funding has been pivotal in enabling us to move forward with the launch of our US Phase 3 trial before the end of the year. This critical study marks a key milestone in our pursuit of FDA approval for our nasal photodisinfection technology. We're thrilled by the strong engagement from our clinical trial investigators and hospital research teams and are excited to commence the trial with the support of our clinical trial partner, HCA Healthcare." Ondine's nasal photodisinfection is a 5-minute, non-invasive procedure that rapidly decolonizes the nose of infection-causing pathogens without the use of antibiotics. This innovative approach avoids contributing to antimicrobial resistance (AMR). The process involves applying a proprietary photosensitive agent to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light. The light activates the agent, producing an oxidative burst that destroys bacteria, viruses and fungi in a single treatment. Nasal decolonization is recommended in the 2016 WHO Global guidelines for the prevention of surgical site infections,[1] and the Society for Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023, recommend nasal decolonization for major surgical procedures.[2] |
Posted at 28/10/2024 08:16 by bamboo2 RNS non. Ondine continues commercial growthOndine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has made significant progress with the commercial roll-out of its novel nasal decolonization technology, Steriwave®, in both Canada and the UK. Steriwave is a simple 5-minute procedure that reduces healthcare-associate In the UK, two of the largest NHS Trusts, King's College Hospital NHS Trust and Leeds Teaching Hospitals NHS Trust, are initiating Steriwave treatment prior to surgery. Recently Ondine announced that has partnered with Mölnlycke Health Care, a world-leading MedTech company that specializes in innovative solutions for wound care and surgical procedures, to bring Ondine's Steriwave® nasal decolonization technology to the United Kingdom, EU, and Middle East markets. In Canada, Steriwave is being used routinely in five (half) of the country's top 10 largest hospitals: Royal Alexandra (Alberta), The Ottawa Hospital - Civic Campus (Ontario), Vancouver General (BC), University of Alberta Hospital, and the Queen Elizabeth II Hospital (Nova Scotia).[1] In the last few months, five additional Canadian healthcare facilities have started using Steriwave to decolonize patients undergoing orthopedic surgery. These include University Hospital of Northern British Columbia, Royal Inland Hospital, Eagle Ridge Hospital, Okanagan Health Surgery Centre, and Hawkesbury General Hospital. Steriwave is also being used in all five of British Columbia's Health Authorities and benefitting from expanding regional adoption. For example, Royal Inland is the fourth hospital in Canada's British Columbia Interior Health Authority to adopt Steriwave alongside Kelowna General, Penticton Regional, and Kootenay Boundary. Eagle Ridge Hospital became the third hospital to embrace Steriwave in the Fraser Health Authority, following Burnaby Hospital, one of the largest hospitals outside the city of Vancouver and the Royal Columbian Hospital, which will be the first hospital to trial Steriwave to prevent infections in ICUs. The four major hospitals in the Vancouver Coastal Health Authority - the first to adopt nasal photodisinfection - have deployed Steriwave in their presurgical infection prevention protocols. Nicole Walby, Clinical Operations Manager at Interior Health Authority, commented: "Steriwave has been fully embraced by patients and staff alike, with patients and their families feeling reassured by the added protection. It's made a noticeable difference at our facility, bringing a sense of ease and comfort to an otherwise serious environment. Preventing surgical site infection through important tools such as Steriwave is a top priority for our clinicians in upholding and improving patient experiences." One in nine hospital patients in Canada gets an HAI resulting in approximately 12,000 deaths a year.[2] HAIs are also becoming harder to treat due to rising rates of AMR which are making some commonly used antibiotics ineffective.[3] This has meant that one in 19 deaths in Canada is now attributable to antibiotic-resistant infections.[4] The cost of AMR to the Canadian healthcare sector is also projected to increase from $1.4 billion to $7.6 billion per year by 2050.[5] Steriwave is a novel antimicrobial treatment that uses a proprietary light-activated agent to decolonize the nose and rapidly eliminate infection-causing pathogens. The agent is applied to each nostril using a nasal swab and then illuminated with a specific wavelength of red light. The light activates the photodynamic agent, causing an oxidative burst that destroys infection-causing bacteria, viruses and fungi in a single, 5-minute treatment. The process works so rapidly that pathogens do not have the opportunity to develop resistance, making it a viable alternative to antibiotics. |
Posted at 10/5/2024 06:12 by z1co 10/05/2024:ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or the "Company") ECDC report shows HAIs are increasing antibiotic use A third of microorganisms causing HAIs (healthcare-associat Ondine Biomedical (LON: OBI): A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore the need for Ondine's light-activated antimicrobial technology, a much-needed innovation in the face of growing antibiotic resistance. The report reveals an alarming increase in antibiotic use and rising resistance and finds that 4.3 million patients in EU/EEA hospitals are affected by healthcare-associate The report, "Point prevalence survey of healthcare-associate ECDC Director Dr. Andrea Ammon said: "Healthcare-associat With the threat of antibiotic-resistant HAIs increasing year-on-year, there is a growing need for effective antimicrobials which do not generate resistance. Antimicrobial resistance (AMR) is responsible for 1.27 million deaths a year and is one of humanity's most urgent global public health threats.[1] Ondine's Steriwave light-activated antimicrobial technology is highly effective against all types of pathogens-viruses, bacteria and fungi-including those that cause HAIs, even those resistant to antibiotics. Steriwave is a broad-spectrum light-activated antimicrobial that uses a patented photosensitizer and associated red light to destroy pathogens in the nose. The nose is a major reservoir of bacteria, fungi, and viruses, which can spread from there to cause serious infections. Unlike traditional antibiotics, Steriwave is immediately effective with a single five-minute treatment and does not trigger AMR. In 2023, Ondine presented research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demonstrating that Steriwave was highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria.[2] Ondine's Steriwave technology is already used in the UK in the NHS and extensively in hospitals across Canada to prevent HAIs. In 2024, hospitals in Spain became the first in the EU to adopt this groundbreaking technology. The prestigious Hospital Universitario La Paz (HULP), a large tertiary hospital in Madrid with 1,308 beds, is one of three Spanish hospitals using Steriwave. According to the latest ECDC HAI surveillance report, the prevalence rate of HAIs in Spain is 8.2% compared to the median of 6.8%. Spain also had higher rates of antibiotic usage, with over 45% of patients with an HAI receiving antibiotics. More than 150,000 patients have been treated with Steriwave to date, and no serious side effects have been reported. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
